Efficacy, safety and tolerability of recombinant factor VIII (REFACTO®) in patients with haemophilia A: Interim data from a postmarketing surveillance study in Germany and Austria

Haemophilia

Volumn 13, Issue 2, 2007, Pages 131-143

  Pollmann, H ^a   Externest, D ^b   Ganser, A ^c   Eifrig, B ^d   Kreuz, W ^e   Lenk, H ^f   Pabinger, I ^g   Schramm, W ^h   Schwarz, T F ⁱ   Zimmermann, R ^j   Zavazava, N ^k   Oldenburg, J ^l   Klamroth, R ^m  

^a Institut für Thrombophilie und Hämostaseologie   (Germany)

^b PFIZER INC   (United States)

^c LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁱ Stiftung Juliusspital   (Germany)

^j SRH Kurpfalzkrankenhaus   (Germany)

^k UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^l UNIVERSITY HOSPITAL BONN   (Germany)

^m VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

more..

Author keywords

Efficacy; Haemophilia A; Post marketing surveillance; Recombinant factor VIII; REFACTO; Tolerability

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADOLESCENT; ADULT; AGED; ALERTNESS; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; AUSTRIA; BLEEDING; CHILD; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FALLING; GERMANY; HEALING IMPAIRMENT; HEART PALPITATION; HEMOLYSIS; HEMOPHILIA A; HUMAN; INFANT; INJURY; KIDNEY COLIC; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OTITIS; PATIENT COMPLIANCE; PHIMOSIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RHINITIS; SIDE EFFECT; SWEATING; THROMBOCYTOPENIA; TOXOPLASMOSIS; TREATMENT RESPONSE; VISUAL IMPAIRMENT;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AUSTRIA; CHILD; CHILD, PRESCHOOL; COAGULANTS; FACTOR VIII; GERMANY; HEMOPHILIA A; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK MANAGEMENT; TREATMENT OUTCOME;

EID: 33846916506     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01416.x     Document Type: Article

References (47)

1. Klinge J, Ananyeva NM, Hauser CAE, Saenko EL. Hemophilia A - from basic science to clinical practice. Semin Thromb Hemost 2002; 28: 309-22.
2. Hoyer LW. Hemophilia A. N Engl J Med 1994; 330: 38-47.
3. Bolton-Maggs PHB, Pasi KJ. Haemophilias A and B. Lancet 2003; 361: 1801-9.
4. Mannucci PM, Giangrande PL. Choice of replacement therapy for hemophilia: Recombinant products only ? Hematol J 2000; 1: 72-6.
5. Eriksson RK, Fenge C, Lindner-Olsson E et al. The manufacturing process for B-domain deleted recombinant factor VIII. Semin Hematol 2001; 38 (suppl. 4): 24-31.
6. Charlebois TS, O'connell BD, Adamson SR et al. Viral safety of B-domain deleted recombinant factor VIII. Semin Hematol 2001; 38 (suppl. 4): 32-9.
7. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Semin Hematol 2001; 38: 44-51.
8. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Semin Hematol 2001; 38: 52-9.
9. Lusher JM, Lee CA, Kessler CM, Bedrosian CL. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9: 38-49.
10. Lusher JM, Roth DA. The safety and efficacy of B-domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: An update. Haemophilia 2005; 11: 292-3.
11. Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol 2004; 127: 379-91.
12. Dimichele D. Inhibitors: Resolving diagnostic and therapeutic dilemmas. Haemophilia 2002; 8: 280-7.
13. Saint-Remy JM, Lacroix-Desmazes S, Oldenburg J. Inhibitors in haemophilia: Pathophysiology. Haemophilia 2004; 10 (suppl. 4): 146-51.
14. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert A-K, for the MIBS Study Group. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167-72.
15. Oldenburg J, Brackmann HH, Schwaab R. Risk factors for inhibitor development in hemophilia A. Haematologica 2000; 85 (suppl.): 7-13.
16. Oldenburg J, Schroder J, Brackmann HH, Muller-Reible C, Schwaab R, Tuddenham E. Environmental and genetic factors influencing inhibitor development. Semin Hematol 2004; 41 (suppl. 1): 82-8.
17. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: A systematic review. Haemophilia 2003; 9: 418-35.
18. Gringeri A, Tagliaferri A, Tagariello G et al. Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII. Br J Haematol 2004; 126: 398-404.
19. Hoots WK, Lusher J. High-titer inhibitor development in hemophilia A: lack of product specificity [letter]. J Thromb Haemost 2004; 2: 358-9.
20. Suiter TM. First and next generation native rFVIII in the treatment of hemophilia A. What has been achieved? Can patients be switched safely ? Semin Thromb Hemost 2002; 28: 277-84.
21. Scharrer I, Ehrlich HJ. Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII. Haemophilia 2001; 7: 346-8.
22. Lassila R, Rothschild C, De Moerloose P et al. Recommendations for postmarketing surveillance studies in haemophilia and other bleeding disorders. Haemophilia 2005; 11: 353-9.
23. European Commission. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use; http://europa.eu.int/eurlex/pri/en/oj/dat/2001/l_121/ l_12120010501en00340044.pdf 2004.
24. Smith MP, Giangrande P, Pollman H et al. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A. Haemophilia 2005; 11: 444-51.
25. Schramm W, Royal S, Kroner B et al. Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia 2002; 8: 33-43.
26. Fischer K, Astermark J, Van Der Bom JG et al. Prophylactic treatment for severe haemophilia: Comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002; 8: 753-60.
27. van den Berg HM, Fischer K. Prophylaxis for severe hemophilia: experience from Europe and the United States. Semin Thromb Hemost 2003; 29: 49-54.
28. Tarantino MD, Collins PW, Hay CRM et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/ albumin-free method: Pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004; 10: 428-37.
29. Teitel JM, Barnard D, Israels S, Lillicrap D, Poon MC, Sek J. Home management of haemophilia. Haemophilia 2004; 10: 118-33.
30. Blanchette VS, Manco-Johnson M, Santagostino E, Ljung R. Optimizing factor prophylaxis for the haemophilia population: Where do we stand? Haemophilia 2004; 10 (suppl. 4): 97-104.
31. Carcao M, Ungar WJ, Feldman BM. Cost-utility analysis in evaluating prophylaxis in haemophilia. Haemophilia 2004; 10 (suppl. 1): 50-7.
32. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001; 7: 392-6.
33. Aygören-Pürsün E, Scharrer I, the German Kogenate Study Group. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. Thromb Haemost 1997; 78: 1352-6.
34. Rothschild C, Scharrer I, Brackmann HH et al. European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients. Haemophilia 2002; 8 (suppl. 2): 10-14.
35. Seremetis S, Lusher JM, Abildgaard CF et al. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: Conclusions of a 5-year study of home therapy. Haemophilia 1999; 5: 9-16.
36. Lusher J, Abildgaard C, Arkin S et al. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: Final report on a hallmark clinical investigation. J Thromb Haemost 2004; 2: 574-83.
37. White II GC, Courter S, Bray GL, Lee M, Gomperts ED, The Recombinate Previously Treated Patient Study Group. A multicenter study of recombinant factor VIII (Recombinate TM) in previously treated patients with hemophilia A. Thromb Haemost 1997; 77: 660-7.
38. Kreuz W, Gill JC, Rothschild C et al. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A. Results of an international clinical investigation. Thromb Haemost 2005; 93: 457-67.
39. Mannucci PM. Impact of recombinant factor VIII on hemophilia care. Vox Sang 1994; 67 (suppl. 3): 49-52.
40. Poonnoose PM, Srivastava A. Functional assessment of arthropathy - an international perspective. Semin Hematol 2006; 43 (suppl. 1): S27-32.
41. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 5: 145-54.
42. Giangrande PLF, for the KOGENATE® Bayer Study Group. Safety and efficacy of KOGENATE® Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs). Haemophilia 2002; 8 (suppl. 2): 19-22.
43. Yoshioka A, Fukutake K, Takamatsu J, Shirahata A. Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A. Int J Hematol 2003; 78: 467-74.
44. DiMichele DM. Inhibitors in haemophilia: A primer. Haemophilia 2000; 6 (suppl. 1): 38-40.
45. Ewenstein BM, Gomperts ED, Pearson S, O'Banion ME. Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/ Bioclate®): A prospective pharmacovigilance study. Haemophilia 2004; 10: 491-8.
46. Oldenburg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EG, Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997; 77: 238-42.
47. Fakharzadeh SS, Kazazian Jr HH. Correlation between factor VIII genotype and inhibitor development in hemophilia A. Semin Thromb Hemost 2000; 26: 167-71.